BioSpace News Archive

Orpheris, a wholly-owned subsidiary of Ashvattha Therapeutics, a biotech company focused on developing novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in inflammatory, oncology and ocular diseases, today announced enrollment of the first patients in its multicenter Phase 2 PRANA clinical study of the HDT,

Virpax® Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that it has entered into a cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), an institute/center of the National Institutes of Health (NIH), U.S. Department of Health and Human Services.

ALR Technologies Inc. (“ALRT”) (OTCQB: ALRT), is pleased to announce that its wholly owned subsidiary ALR Technologies SG Pte. Ltd has executed a Memorandum of Understanding (MOU) with Diabetes Singapore , a full member in the International Diabetes Federation (IDF). The MOU outlines a collaboration between the two parties to raise the diabetes management standard in Singapore. The collaboration intends to develop a diabetes management program

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced today that its U.S. joint venture partner, GtreeBNT, is accelerating the ARISE-3 phase 3 clinical trial for dry eye syndrome

Previously completed positive, pivotal ADVANCE-1 trial sufficient with single additional Phase 3 efficacy trial for NDA in Alzheimer’s disease agitation Initiation of Phase 3, placebo-controlled, randomized-withdrawal efficacy trial on track for 4Q 2020 Initiation of long-term safety trial in patients with Alzheimer’s disease agitation expected in 4Q 2020 No treatments are currently approved for the treatment of Alzheimer’s disease agitation

Mindset Pharma (“Mindset”), a leading drug discovery and development business focused on next-generation psychedelic medicines to treat neuropsychiatric indications with unmet needs, announces today the preliminary screening results of certain patent-pending compounds.

Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) , today announced that its wholly owned subsidiary, Dialco Medical Inc. ( “Dialco” ) has been granted 510(k) clearance by the United States Food and Drug Administration ( “FDA” ) for DIMI to tr

Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, today announced that the topp

CollPlant’s photocurable regenerative filler[1] combines the advantages of collagen and hyaluronic acid for skin regeneration

Formsense, a leading wearable technology and smart apparel company, has been chosen as technology partner for a $2.4M grant from the National Institutes of Health (NIH) that includes an interdisciplinary team of world-renowned researchers in rehabilitation sciences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200831005080/en/ Smart ring from leading wea